An open label, randomized, parallel-group study assessing the effect of Cytochrome P450 (Cyp) 3A4 inhibition on the pharmacokinetics and safety of Quizartinib and its active metabolite, Ac886

Trial Profile

An open label, randomized, parallel-group study assessing the effect of Cytochrome P450 (Cyp) 3A4 inhibition on the pharmacokinetics and safety of Quizartinib and its active metabolite, Ac886

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Quizartinib (Primary) ; Fluconazole; Ketoconazole
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top